| 41. |
- Aktas, A, et al.
(author)
-
Measurement of deeply virtual Compton scattering at HERA
- 2005
-
In: European Physical Journal C. Particles and Fields. - : Springer Science and Business Media LLC. - 1434-6044. ; 44:1, s. 1-11
-
Journal article (peer-reviewed)abstract
- A measurement is presented of elastic deeply virtual Compton scattering gamma* p -> gamma p made using e(+) p collision data corresponding to a luminosity of 46.5 pb(-1), taken with the H1 detector at HERA. The cross section is measured as a function of the photon virtuality, Q(2), the invariant mass of the gamma* p system, W, and for the first time, differentially in the squared momentum transfer at the proton vertex, t, in the kinematic range 2 < Q(2) < 80 GeV2, 30 < W < 140 GeV and vertical bar t vertical bar < 1 GeV2. QCD based calculations at next-to-leading order using generalized parton distributions can describe the data, as can colour dipole model predictions.
|
|
| 42. |
- Aktas, A, et al.
(author)
-
Measurement of dijet cross sections in ep interactions with a leading neutron at HERA
- 2005
-
In: European Physical Journal C. Particles and Fields. - : Springer Science and Business Media LLC. - 1434-6044. ; 41:3, s. 273-286
-
Journal article (peer-reviewed)abstract
- Measurements are reported of the production of dijet events with a leading neutron in ep interactions at HERA. Differential cross sections for photoproduction and deep inelastic scattering are presented as a function of several kinematic variables. Leading order QCD simulation programs are compared with the measurements. Models in which the real or virtual photon interacts with a parton of an exchanged pion are able to describe the data. Next-to-leading order perturbative QCD calculations based on pion exchange are found to be in good agreement with the measured cross sections. The fraction of leading neutron dijet events with respect to all dijet events is also determined. The dijet events with a leading neutron have a lower fraction of resolved photon processes than do the inclusive dijet data.
|
|
| 43. |
- Aktas, A, et al.
(author)
-
Measurement of F-2(c(c)over-bar) and F-2(b(b)over-bar) at high Q(2) using the H1 vertex detector at HERA
- 2005
-
In: European Physical Journal C. Particles and Fields. - : Springer Science and Business Media LLC. - 1434-6044. ; 40:3, s. 349-359
-
Journal article (peer-reviewed)abstract
- Measurements are presented of inclusive charm and beauty cross sections in e(+)p collisions at HERA for values of photon virtuality Q(2) > 150 GeV2 and of inelasticity 0.1 < y < 0.7. The charm and beauty fractions are determined using a method based on the impact parameter, in the transverse plane, of tracks to the primary vertex, as measured by the H1 vertex detector. The data are divided into four regions in Q(2) and Bjorken x, and values for the structure functions F-2(c (c) over bar) and F-2(b (b) over bar) are obtained. The results are found to be compatible with the predictions of perturbative quantum chromodynamics.
|
|
| 44. |
- Aktas, A, et al.
(author)
-
Search for leptoquark bosons in ep collisions at HERA
- 2005
-
In: Physics Letters. Section B: Nuclear, Elementary Particle and High-Energy Physics. - : Elsevier BV. - 0370-2693. ; 629:1, s. 9-19
-
Journal article (peer-reviewed)abstract
- A search for scalar and vector leptoquarks coupling to first generation fermions is performed using the e(+) p and e(-) p scattering data collected by the H1 experiment between 1994 and 2000. The data correspond to a total integrated luminosity of 117 pb(-1). No evidence for the direct or indirect production of such particles is found in data samples with a large transverse momentum final state electron or with large missing transverse momentum. Constraints on leptoquark models are established. For leptoquark couplings of electromagnetic strength, leptoquarks with masses up to 275-325 GeV are ruled out at 95% confidence level. These limits improve and supercede earlier H1 limits based on subsamples of the data used here.
|
|
| 45. |
- Aktas, A, et al.
(author)
-
A determination of electroweak parameters at HERA
- 2006
-
In: Physics Letters. Section B: Nuclear, Elementary Particle and High-Energy Physics. - : Elsevier BV. - 0370-2693. ; 632:1, s. 35-42
-
Journal article (peer-reviewed)abstract
- Using the deep inelastic e(+) p and e(-) p charged and neutral current scattering cross sections previously published, a combined electroweak and QCD analysis is performed to determine electroweak parameters accounting for their correlation with parton distributions. The data used have been collected by the HI experiment in 1994-2000 and correspond to an integrated luminosity of 117.2 pb(-1). A measurement is obtained of the W propagator mass in charged current ep scattering. The weak mixing angle sin(2)theta w is determined in the on-mass-shell renormalisation scheme. A first measurement at HERA is made of the light quark weak couplings to the Z(0) boson and a possible contribution of right-handed isospin components to the weak couplings is investigated. (c) 2005 Elsevier B.V. All rights reserved.
|
|
| 46. |
- Aktas, A, et al.
(author)
-
Measurement of beauty production at HERA using events with muons and jets
- 2005
-
In: European Physical Journal C. Particles and Fields. - : Springer Science and Business Media LLC. - 1434-6044. ; 41:4, s. 453-467
-
Journal article (peer-reviewed)abstract
- A measurement of the beauty production cross section in ep collisions at a centre-of-mass energy of 319 GeV is presented. The data were collected with the H1 detector at the HERA collider in the years 1999-2000. Events are selected by requiring the presence of jets and muons in the final state. Both the long lifetime and the large mass of b-flavoured hadrons are exploited to identify events containing beauty quarks. Differential cross sections are measured in photoproduction, with photon virtualities Q(2) < 1 GeV2, and in deep inelastic scattering, where 2 < Q(2) < 100 GeV2. The results are compared with perturbative QCD calculations to leading and next-to-leading order. The predictions are found to be somewhat lower than the data.
|
|
| 47. |
- Aktas, A, et al.
(author)
-
Measurement of Fc(c)over-bar(2) and Fb(b)over-bar(2) at low Q(2) and x using the H1 vertex detector at HERA
- 2006
-
In: European Physical Journal C. Particles and Fields. - : Springer Science and Business Media LLC. - 1434-6044. ; 45:1, s. 23-33
-
Journal article (peer-reviewed)abstract
- Measurements are presented of inclusive charm and beauty cross sections in e(+)p collisions at HERA for values of photon virtuality 12 <= Q(2) = 60 GeV2 and of the Bjorken scaling variable 0.0002 <= x <= 0.005. The fractions of events containing charm and beauty quarks are determined using a method based on the impact parameter, in the transverse plane, of tracks to the primary vertex, as measured by the H1 vertex detector. Values for the structure functions F-2(cc) and F-2(bb) are obtained. This is the first measurement of F-2(bb) in this kinematic range. The results are found to be compatible with the predictions of perturbative quantum chromodynamics and with previous measurements of F-2(cc).
|
|
| 48. |
|
|
| 49. |
|
|
| 50. |
- Abe, O, et al.
(author)
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
- 2005
-
In: The Lancet. - 1474-547X. ; 365:9472, s. 1687-1717
-
Journal article (peer-reviewed)abstract
- Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
|
|
